NasdaqGS · Biotechnology

LENZ Therapeutics, Inc. (LENZ)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Buy+412.8%

$24.00 average target

$4.68+0.02 (+0.4%)Latest market snapshot · Yahoo Finance

Market cap$147.0M

Cash$220.0M

Quarterly burn$38.7M

Pipeline assets2

Short float59.5%

Market context

LENZ Stock Chart

Loading interactive chart…

Chart provided by TradingView. Market data may be delayed.

Next catalyst

No dated milestone

Review the pipeline for undated development programs.

View pipeline & catalysts

Company profile

About LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.